Sign In
Buy PRCT
$16.69
-0.86 (-4.90%)
At Close: Jul 24, 2026
Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
09:15pm, Monday, 14'th Jul 2025
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transf
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
04:03pm, Tuesday, 29'th Apr 2025
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
04:03pm, Thursday, 24'th Apr 2025
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24,
PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
02:37pm, Thursday, 24'th Apr 2025
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Rez
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 24'th Apr 2025
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago.
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
07:00am, Thursday, 24'th Apr 2025
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing t
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
04:03pm, Thursday, 10'th Apr 2025
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment gl
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a random
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
08:00am, Friday, 14'th Mar 2025
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing tra
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
04:42am, Tuesday, 11'th Mar 2025
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables busines
PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript
12:42am, Wednesday, 26'th Feb 2025
PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates
06:25pm, Tuesday, 25'th Feb 2025
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.54 per share a year ago.
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
04:02pm, Tuesday, 25'th Feb 2025
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing tran
SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative s
PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Thursday, 16'th Jan 2025
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
